Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-05

Clinical Trial Update: A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD [Phase 2]

View source ↗

Summary

Phase 2 pilot dose-response biomarker study of brexpiprazole in PTSD was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • brexpiprazole (brexpiprazole)

Snippet

Sponsor: Duke University | Conditions: Post Traumatic Stress Disorder | Phase 2 | Status: TERMINATED | Results posted: 2019-03-05